Mulitude Therapeutics

top of page

MTlogo w ABT.jpg

Multitude Therapeutics

Innovative, Effective Drugs for the great multitude

About Us

Multitude Therapeutics is a clinical stage biopharmaceutical company established in 2019 to leverage its unparalleled target and antibody discovery arrays (Human Membrane Proteome MabArrayTM or HMP-MabArrayTM) , combined with a proprietary ADC platform (T1000), to develop novel therapeutics for cancer treatment. The powerful synergy derived from combining MabArrayTM and T1000 enables Multitude to build an atlas of ADCs that has the potential to treat malignancies with high unmet medical needs. Multitude’s pipeline includes both first-in-class and best-in-class antibody-drug conjugates (ADCs) for solid and hematological tumors.

Contact

Address

3698 Haven Avenue, Suite A

Redwood City, CA 94063, USA

Unit 10, No. 159 Tianzhou Road, Xuhui District, Shanghai 200235

Multitude Therapeutics (Australia) Pty Ltd
Level 7, 330 Collins Street, Melbourne, Victoria 3000, Australia

Email: info@multitudetherapeutics.com

bottom of page